CO5650243A2 - Modulador del receptor canabinoide - Google Patents

Modulador del receptor canabinoide

Info

Publication number
CO5650243A2
CO5650243A2 CO05129098A CO05129098A CO5650243A2 CO 5650243 A2 CO5650243 A2 CO 5650243A2 CO 05129098 A CO05129098 A CO 05129098A CO 05129098 A CO05129098 A CO 05129098A CO 5650243 A2 CO5650243 A2 CO 5650243A2
Authority
CO
Colombia
Prior art keywords
optionally substituted
group
atom
ring
formula
Prior art date
Application number
CO05129098A
Other languages
English (en)
Inventor
Shigenori Ohkawa
Tetsuya Tsukamoto
Yoshihiro Kiyota
Mika Goto
Shouzou Yamamoto
Masato Shimojou
Masaki Seto
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of CO5650243A2 publication Critical patent/CO5650243A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/83—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/86—Benzo [b] furans; Hydrogenated benzo [b] furans with an oxygen atom directly attached in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

1.- Un modulador del receptor canabinoide, caracterizado porque contiene un compuesto representado por la fórmula (lo) en donde, X es un átomo de oxígeno, un átomo de azufre opcionalmente substituido o un grupo imino opcionalmente substituido, RO es un grupo acilamino opcionalmente substituido, el anillo Ao es un anillo de benceno el cual puede además tener un substituyente además de Ro, y el anillo B es un heterociclo de 5 miembros opcionalmente substituido, o una sal del mismo o un profármaco del mismo.2.- El modulador de conformidad con la reivindicación 1, caracterizado porque el compuesto representado por la Fórmula (lo) o una sal del mismo o un profármaco del mismo es un compuesto representado por la fórmula (I) en donde, X es un átomo de oxígeno, un átomo de azufre opcionalmente substituido o un grupo imino opcionalmente substituido, R1, R2, R3 y R4 son independientemente un átomo de hidrógeno, un grupo hidrocarburo opcionalmente substituido, un grupo heterocíclico opcionalmente substituido, un grupo hidroxilo opcionalmente substituido, un grupo mercapto opcionalmente substituido o un grupo amino opcionalmente substituido, o R2 y R3 pueden tomarse juntos para formar un enlace, o R1 y R2 pueden tomarse con el átomo de carbono adyacente para formar un anillo opcionalmente substituido, Y es -CO-, -SO-, ó SO2-, R5 es un átomo de hidrógeno o un grupo hidrocarburo opcionalmente substituido, R6 es un átomo de hidrógeno, un grupo hidrocarburo opcionalmente substituido, un grupo hidroxilo opcionalmente substituido o un grupo amino opcionalmente substituido, o R5 y R6 pueden tomarse con el átomo de carbono o átomo de azufre adyacente y átomo de nitrógeno para formar un anillo opcionalmente substituido, y el anillo A es un anillo de benceno el cual puede además tener un substituyente además de un grupo representado por la siguiente fórmula en donde, cada uno de los símbolo tiene el mismo significado como se describe arriba, o una sal del mismo o un profármaco del mismo.
CO05129098A 2003-06-26 2005-12-22 Modulador del receptor canabinoide CO5650243A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003182039 2003-06-26

Publications (1)

Publication Number Publication Date
CO5650243A2 true CO5650243A2 (es) 2006-06-30

Family

ID=33549544

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05129098A CO5650243A2 (es) 2003-06-26 2005-12-22 Modulador del receptor canabinoide

Country Status (24)

Country Link
US (4) US7465815B2 (es)
EP (1) EP1637527B1 (es)
KR (1) KR101138673B1 (es)
CN (1) CN1816536B (es)
AU (1) AU2004252005B2 (es)
BR (1) BRPI0411740A (es)
CA (1) CA2531020C (es)
CO (1) CO5650243A2 (es)
CR (1) CR8152A (es)
CY (1) CY1114472T1 (es)
DK (1) DK1637527T3 (es)
ES (1) ES2420932T3 (es)
HK (1) HK1088305A1 (es)
HR (1) HRP20130638T1 (es)
IL (1) IL172577A0 (es)
MX (1) MXPA05013652A (es)
NO (1) NO335769B1 (es)
NZ (1) NZ544298A (es)
PL (1) PL1637527T3 (es)
PT (1) PT1637527E (es)
SI (1) SI1637527T1 (es)
TW (1) TWI329013B (es)
WO (1) WO2005000829A1 (es)
ZA (1) ZA200510304B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1636340A4 (en) * 2003-06-18 2009-02-11 Scripps Research Inst COMPLEMENTS TO THE GENETIC CODE OF UNNATURATIVE REACTIVE AMINO ACIDS
ES2420932T3 (es) * 2003-06-26 2013-08-27 Takeda Pharmaceutical Company Limited Modulador del receptor de cannabinoides
MX2007007453A (es) 2004-12-22 2007-07-19 Ciba Sc Holding Ag Agentes antirradicales.
US20080194557A1 (en) * 2007-01-18 2008-08-14 Joseph Barbosa Methods and compositions for the treatment of pain, inflammation and cancer
US9079854B2 (en) 2007-07-13 2015-07-14 The Cleveland Clinic Foundation Hydrazone modulators of cannabinoid receptors
US8440832B2 (en) * 2007-07-13 2013-05-14 Board Of Regents, The University Of Texas System Heterocyclic modulators of cannabinoid receptors
US8309595B2 (en) * 2007-07-13 2012-11-13 Board Of Regents, The University Of Texas System Hydrazone modulators of cannabinoid receptors
US9394267B2 (en) 2007-07-13 2016-07-19 The Cleveland Clinic Foundation Heterocyclic modulators of cannabinoid receptors
ES2716407T3 (es) 2007-11-30 2019-06-12 Zynerba Pharmaceuticals Inc Profármacos de tetrahidrocannabinol, composiciones que comprenden profármacos de tetrahidrocannabinol y métodos para uso de los mismos
PL2406243T3 (pl) 2009-03-10 2014-10-31 Takeda Pharmaceuticals Co Pochodne benzofuranu
US20130059890A1 (en) * 2009-12-18 2013-03-07 Sydney West Area Health Service Antiviral agents
CN103748085A (zh) 2011-06-09 2014-04-23 诺华股份有限公司 杂环磺酰胺衍生物
WO2013025984A2 (en) * 2011-08-18 2013-02-21 Temple University Cannabinoid receptor treatments
CN104936596A (zh) 2012-07-13 2015-09-23 克利夫兰临床基金会 神经保护性cb2受体激动剂
CN105878251B (zh) * 2016-04-22 2019-04-09 上海市同济医院 帕金森病动物模型的制备方法及其用途
CN107935981B (zh) * 2016-10-12 2020-10-09 中国科学院上海药物研究所 3,4-二氢-1-苯并氧杂卓类衍生物、其制备方法和用途
CN109503533B (zh) * 2019-01-04 2022-06-24 湖南大学 一种苯并呋喃酮类化合物及其高效催化合成方法
CN111072613B (zh) * 2019-11-29 2023-03-24 五邑大学 一类松萝酸类衍生物及其制备方法和在制备抗老年痴呆药物中的应用
US11787775B2 (en) * 2020-07-24 2023-10-17 Genentech, Inc. Therapeutic compounds and methods of use

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE68675B1 (en) * 1990-11-01 1996-07-10 Takeda Chemical Industries Ltd Aminocoumaran derivatives their production and use
CA2098912A1 (en) * 1990-12-28 1992-06-29 Tatsuki Shiota Benzoxa condensed ring compound, process for producing the same and pharmaceutical composition comprising the same
EP0539709A1 (en) * 1991-09-18 1993-05-05 FUJIREBIO Inc. 3,5-Dihydroxyheptanoic acid derivatives and lactones thereof as HMG-CoA reductase inhibitors
US5596106A (en) 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
US5684002A (en) * 1994-09-07 1997-11-04 The Procter & Gamble Company Dihydorbenzofuran and related compounds useful as anti-inflammatory agents
IT1271266B (it) * 1994-12-14 1997-05-27 Valle Francesco Della Impiego terapeutico di ammidi di acidi mono e bicarbossilici con amminoalcoli,selettivamente attive sul recettore periferico dei cannabinoidi
US5684041A (en) 1996-02-01 1997-11-04 The Procter & Gamble Company Dihydrobenzofuran and related compounds useful as anti-inflammatory agents
CA2264231A1 (en) * 1996-08-29 1998-03-05 Takeda Chemical Industries, Ltd. Cyclic ether compounds as sodium channel modulators
JP4160136B2 (ja) * 1996-08-29 2008-10-01 武田薬品工業株式会社 縮合環状エーテル類、その製造法および剤
DE19706903A1 (de) * 1997-02-21 1998-08-27 Bayer Ag Verwendung von bekannten Agonisten des zentralen Cannabinoid-Rezeptors CB 1
EP0988289A2 (en) * 1997-06-05 2000-03-29 Takeda Pharmaceutical Company Limited Heterocyclic compounds, their production and use
CN1297550C (zh) 1998-12-04 2007-01-31 武田药品工业株式会社 苯并呋喃衍生物及其制备和用途
DE69930308T2 (de) 1998-12-11 2006-11-30 Virginia Commonwealth University Selektive 5-ht 6-rezeptor-liganden
JP2000256323A (ja) 1999-01-08 2000-09-19 Japan Tobacco Inc ２−オキソキノリン化合物及びその医薬用途
US7008940B1 (en) * 1999-08-20 2006-03-07 Takeda Pharmaceutical Company Limited Dihydrobenzofuran derivatives, process for the preparing thereof and agents
AU2001292350A1 (en) * 2000-10-05 2002-04-15 Takeda Chemical Industries Ltd. Promoters for the proliferation and differentiation of stem cells and/or neuron precursor cells
JP2002348239A (ja) * 2000-10-05 2002-12-04 Takeda Chem Ind Ltd 幹細胞・神経前駆細胞の増殖・分化促進剤
AUPR118000A0 (en) * 2000-11-02 2000-11-23 Amrad Operations Pty. Limited Therapeutic molecules and methods
SE0101387D0 (sv) * 2001-04-20 2001-04-20 Astrazeneca Ab Novel compounds
CA2452596C (en) * 2001-07-05 2010-12-21 Takeda Chemical Industries, Ltd. Benzo-fused 5-membered heterocyclic compounds, their production and use
ES2420932T3 (es) * 2003-06-26 2013-08-27 Takeda Pharmaceutical Company Limited Modulador del receptor de cannabinoides

Also Published As

Publication number Publication date
SI1637527T1 (sl) 2013-07-31
CN1816536B (zh) 2012-12-26
TW200503686A (en) 2005-02-01
US20070099990A1 (en) 2007-05-03
MXPA05013652A (es) 2006-02-24
TWI329013B (en) 2010-08-21
WO2005000829A1 (ja) 2005-01-06
NO20060426L (no) 2006-02-07
KR20060066677A (ko) 2006-06-16
NO335769B1 (no) 2015-02-09
DK1637527T3 (da) 2013-07-01
US20090023800A1 (en) 2009-01-22
US7465815B2 (en) 2008-12-16
CA2531020C (en) 2014-03-25
HK1088305A1 (en) 2006-11-03
US20080021087A1 (en) 2008-01-24
CY1114472T1 (el) 2016-10-05
ES2420932T3 (es) 2013-08-27
NZ544298A (en) 2009-04-30
BRPI0411740A (pt) 2006-05-23
AU2004252005A1 (en) 2005-01-06
CR8152A (es) 2007-08-28
US20100240743A1 (en) 2010-09-23
ZA200510304B (en) 2007-04-25
EP1637527B1 (en) 2013-04-17
PT1637527E (pt) 2013-06-28
CA2531020A1 (en) 2005-01-06
HRP20130638T1 (en) 2013-08-31
CN1816536A (zh) 2006-08-09
AU2004252005B2 (en) 2010-02-18
KR101138673B1 (ko) 2012-04-24
EP1637527A1 (en) 2006-03-22
US7507841B2 (en) 2009-03-24
IL172577A0 (en) 2006-04-10
PL1637527T3 (pl) 2013-09-30
EP1637527A4 (en) 2008-09-10

Similar Documents

Publication Publication Date Title
CO5650243A2 (es) Modulador del receptor canabinoide
CO6321130A2 (es) Piridinas carboxamidas como inhibidores de la 11 beta-hsd1
CO5721002A2 (es) Derivados de acido 3-(4-benciloxifenil) propanoico
ECSP10010060A (es) Derivados de pirazol sustituídos
CO6231035A2 (es) Novedoso compuesto heteromonociclico que tiene propiedades superiores como agente farmaceutico
CO6160234A2 (es) Nuevos compuestos ciclicos fusionados que presentan una accion moduladora de la funcion del recptor gpr40
CO6160266A2 (es) Derivado de oxopirazina y herbicida
TW200736363A (en) Material for organic electroluminescent device and organic electroluminescent device
CY1109222T1 (el) Παραγωγο συγχωνευμενης κινολινης και χρηση του
GT200600428A (es) Compuestos organicos
UA81468C2 (en) Heteroarylcarbamoylbenzene derivatives
TW200611907A (en) Fused heterocyclic compound
MY139988A (en) Macrocylic inhibitors of hepatitis c virus
GT200500286A (es) Analogos de anilino-pirimidina
CO5611131A2 (es) Derivados de 5-feniltiazol y su uso como inhibidores de pi3 cinasa
AR066962A1 (es) Compuesto heterociclico fusionado
ECSP077274A (es) Derivados de n-2 adamantanil-2-fenoxi-acetamida como inhibidores de deshidrogenasa 11-beta hidroxiesteroide
MX2009006397A (es) Derivados de imidazotiazol.
CO5690607A2 (es) Compuestos de piridina como inhibidores de dipeptidil peptidasa iv
WO2009057784A1 (ja) 複素環化合物
AR068538A1 (es) Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido
CO6210825A2 (es) Derivado de heterocicliden-n-(aril)acetamina
TW200833700A (en) Gold complex and producing method thereof, and organic ultraviolet electroluminescence element using the same
ES2571529T3 (es) Nuevos derivados de isoquinolina sustituida
BRPI0508471A (pt) hidróxi-6-fenilfenantridinas substituìdas por difluoroetóxi

Legal Events

Date Code Title Description
FC Application refused